Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Zhonghua Xue Ye Xue Za Zhi ; 45(2): 178-183, 2024 Feb 14.
Article in Chinese | MEDLINE | ID: mdl-38604795

ABSTRACT

Objective: To investigate the clinical efficacy and safety of ferric derisomaltose injection versus iron sucrose injection in the treatment of iron deficiency anemia (IDA) . Methods: A total of 120 patients with iron deficiency anemia admitted from June 2021 to March 2023 were given intravenous iron supplementation with ferric derisomaltose to assess the efficacy and safety of hemoglobin (HGB) elevation before and after treatment. Simultaneously, the clinical effects of iron supplementation with iron sucrose were compared to those of inpatient patients during the same period. Results: Baseline values were comparable in both groups. Within 12 weeks of treatment, the elevated HGB level in the ferric derisomaltose group was higher than that of the iron sucrose group, with a statistical difference at all time points, and the proportion of HGB increased over 20 g/L in the patients treated for 4 weeks was higher (98.7%, 75.9% ). During the treatment with ferric derisomaltose and iron sucrose, the proportion of mild adverse reactions in the ferric derisomaltose group was slightly lower than that of the iron sucrose group, and neither group experienced any serious adverse reactions. The patients responded well to the infusion treatment, with no reports of pain or pigmentation at the injection site. Conclusion: The treatment of IDA patients with ferric derisomaltose has a satisfactory curative effect, with the advantages of rapidity, accuracy, and safety. Therefore, it is worthy of widespread clinical use.


Subject(s)
Anemia, Iron-Deficiency , Disaccharides , Humans , Ferric Oxide, Saccharated/therapeutic use , Anemia, Iron-Deficiency/drug therapy , Anemia, Iron-Deficiency/chemically induced , Infusions, Intravenous , Retrospective Studies , Ferric Compounds/therapeutic use , Ferric Compounds/adverse effects , Iron , Hemoglobins/analysis , Hemoglobins/therapeutic use
2.
Zhonghua Yi Xue Za Zhi ; 103(34): 2639-2646, 2023 Sep 12.
Article in Chinese | MEDLINE | ID: mdl-37475568

ABSTRACT

Chest tightness variant asthma (CTVA) was first reported and named by Chinese scholars in 2013. It is a new clinical type of asthma characterized by chest tightness as the only or primary symptom, without typical asthma manifestations such as recurrent wheezing and shortness of breath, and without wheezing sounds heard during lung auscultation. The overall epidemiological data on CTVA is currently unavailable. Its pathogenesis is similar to that of typical asthma, involving eosinophilic airway inflammation. Due to the lack of typical clinical manifestations, insufficient knowledge of this disease in some clinicians and some other reasons, CTVA is susceptible to misdiagnosis or missed diagnosis. Currently, the diagnostic criteria for CTVA are: chest tightness as the only or primary symptom, without typical asthma symptoms and signs such as wheezing and shortness of breath, and with any one of the objective indicators of variable airflow limitation. Effective anti-asthma treatment is required, and other diseases that cause chest tightness, such as cardiovascular, digestive, nervous, muscular, and mental diseases should be excluded. CTVA treatment follows that of typical asthma, but the specific treatment duration is uncertain and may require long-term management. Traditional Chinese medicine has shown some therapeutic effects on CTVA. Most CTVA patients have a good prognosis after active anti-asthma treatment. This paper analyzes and summarizes the research of CTVA in China from 2013 and provides new perspectives for further exploration of CTVA.


Subject(s)
Anti-Asthmatic Agents , Asthma , Humans , Respiratory Sounds , Asthma/drug therapy , Dyspnea/drug therapy , China
3.
Neuroscience ; 245: 40-9, 2013 Aug 15.
Article in English | MEDLINE | ID: mdl-23608100

ABSTRACT

Proton magnetic resonance spectroscopy (1H-MRS) can provide noninvasive detection of brain metabolite changes in vivo in Alzheimer's disease (AD). AD is a prevalent neurodegenerative disorder characterized by deposition of ß-amyloid peptides (Aß) in multiple brain regions. Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor whose level has been shown to be decreased in AD. BDNF supplementation can offer improvement in AD. However, the means of evaluation are still relatively limited. In the present study, 1H-MRS was applied to evaluate the therapeutic effects of bilateral intraventricular BDNF infusion into APP+PS1 (amyloid precursor protein+presenilin 1) transgenic mice. For comparison to the 1H-MRS changes in the prefrontal cortex, Morris water maze (MWM) test, Fluoro-Jade B staining and immunofluorescence for Aß, glial fibrillary acidic protein and tropomyosin-related kinase B (TrkB) were also performed. Our results showed that N-acetylaspartate (NAA) levels increased and myo-inositol levels decreased in Tg-BDNF mice compared with Tg-PBS mice. But NAA level in Tg-BDNF mice was still lower than that in wild-type mice at 6weeks after infusion. These changes correlated with increased immunoreactivity of TrkB, reduced compact Aß peptide and FJB+ neurons in Tg-BDNF mice compared to Tg-PBS mice. However, Tg-BDNF mice did not present obvious changes in behavior in the MWM. Taken together, we suggest that 1H-MRS may be a sensitive means of evaluating metabolic changes in response to therapeutic strategies in AD. Moreover, BDNF, may be a viable means of offering trophic support during disease.

4.
Cell Biol Toxicol ; 22(3): 149-58, 2006 May.
Article in English | MEDLINE | ID: mdl-16555001

ABSTRACT

Grape seed proanthocyanidin extract (GPSE) at high doses has been shown to exhibit cytotoxicity that is associated with increased apoptotic cell death. Nitric oxide (NO), being a regulator of apoptosis, can be increased in production by the administration of GSPE. In a chick cardiomyocyte study, we demonstrated that high-dose (500 microg/ml) GSPE produces a significantly high level of NO that contributes to increased apoptotic cell death detected by propidium iodide and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining. It is also associated with the depletion of intracellular glutathione (GSH), probably due to increased consumption by NO with the formation of S-nitrosoglutathione. Co-treatment with L-NAME, a NO synthase inhibitor, results in reduction of NO and apoptotic cell death. The decline in reduced GSH/oxidized GSH (GSSG) ratio is also reversed. N-Acetylcysteine, a thiol compound that reacts directly with NO, can reduce the increased NO generation and reverse the decreased GSH/GSSG ratio, thereby attenuating the cytotoxicity induced by high-dose GSPE. Taken together, these results suggest that endogenous NO synthase (NOS) activation and excessive NO production play a key role in the pathogenesis of high-dose GSPE-induced cytotoxicity.


Subject(s)
Myocytes, Cardiac/drug effects , Nitric Oxide/physiology , Plant Extracts/toxicity , Proanthocyanidins/toxicity , Acetylcysteine/pharmacology , Animals , Cell Death , Cell Survival , Cells, Cultured , Chick Embryo , Dose-Response Relationship, Drug , Drug Interactions , Glutathione/metabolism , Grape Seed Extract
5.
J Mol Cell Cardiol ; 31(10): 1885-95, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10525426

ABSTRACT

Extract from Scutellaria baicalensis Georgi Attenuates Oxidant Stress in Cardiomyocytes. Journal of Molecular and Cellular Cardiology (1999) 31, 1885-1895. Scutellaria baicalensis Georgi is a Chinese herbal medicine used to treat allergic and inflammatory diseases. The medicinal effects of S. baicalensis root may result, in part, from its constituent flavones reported to have antioxidant properties. Since oxidants play multiple roles in cells, we tested whether S. baicalensis could confer protection in a cardiomyocyte model of ischemia and reperfusion. The intracellular fluorescent probes 2',7'-dichlorofluorescin diacetate (DCFH-DA, sensitive to H(2)O(2) and hydroxyl radicals) and dihydroethidium (DHE, sensitive to superoxide) were used to assess intracellular reactive oxygen species (ROS), and propidium iodide (PI) was used to assess viability in cultured embryonic cardiomyocytes. S. baicalensis extract (SbE) quickly attenuated levels of oxidants generated during transient hypoxia and during exposure to the mitochondrial site III inhibitor antimycin A, as measured by DCFH oxidation or by DHE oxidation. These attenuated oxidant levels were associated with improved survival and function. Cell death after ischemia/reperfusion decreased from 47+/-3 % in untreated to 26+/-2 % in S. baicalensis treated cells (P<0.001). After antimycin A exposure, S. baicalensis decreased cell death from 49+/-6 % in untreated to 23+/-4 % in treated cells. Return of contraction occurred in S. baicalensis-treated cells but was not observed in control cells. Other in vitro studies revealed that baicalein, a major flavone component of SbE can directly scavenge superoxide, hydrogen peroxide, and hydroxyl radicals. Collectively, these findings indicate that SbE and its constituent flavones such as baicalein can attenuate oxidant stress and protect cells from lethal oxidant damage in an ischemia-reperfusion model.


Subject(s)
Cell Hypoxia , Flavanones , Flavonoids/pharmacology , Heart/drug effects , Myocardium/cytology , Plant Extracts/pharmacology , Reactive Oxygen Species/physiology , Animals , Cell Hypoxia/drug effects , Cell Survival , Cells, Cultured , Chick Embryo , Drugs, Chinese Herbal , Heart Ventricles , Microscopy, Video , Plant Roots , Plants, Medicinal
6.
Clin Orthop Relat Res ; (188): 303-8, 1984 Sep.
Article in English | MEDLINE | ID: mdl-6380866

ABSTRACT

In 23 dogs, polymethylmethacrylate (PMMA) was safely implanted in the region of the spinal cord. The dogs were treated by bone or cement fixation after anterior excision of a single cervical vertebral body. Fixation was compared at 0-18 weeks, with control values obtained from 11 dogs. Anterior cement fixation did not displace after 18 weeks. The anterior bone graft appeared to achieve adequate fixation strength around six weeks. The strength of the bone-graft fixation increased, while that of cement fixation decreased somewhat with time. At all time intervals, the ratio of energy absorption to structural failure was somewhat higher with bone graft than with PMMA.


Subject(s)
Bone Cements/therapeutic use , Bone Transplantation , Methylmethacrylates/therapeutic use , Spinal Fusion/methods , Animals , Cervical Vertebrae/surgery , Dogs , Drug Evaluation, Preclinical , Ilium/transplantation , Stress, Mechanical , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL